Impedimetric Tumor Detection System

In radiological tests, breast abnormalities are categorized from BIRADS-1 to BIRADS-5 based on the likelihood of cancer. Abnormalities identified as BIRADS-3 require follow-up every 3 to 6 months, while those diagnosed as BIRADS-4a and higher require a biopsy. The limitations of Sonography in detecting these abnormalities often result in delays in patient treatment and necessary biopsies. The Impedimetric Tumor Detection System (ITDS) device is a new and innovative technology where a specially designed probe is inserted into the patient's body under ultrasound guidance and removed after a few seconds, with the test results instantly displayed. ITDS can be particularly beneficial for young patients with dense breast tissue, especially those with BI-RADS3 masses that are difficult to evaluate with mammography. Additionally, patients with BI-RADS3 masses and a family history of breast cancer can also benefit from this system. This device also has important applications in distinguishing simple fibroadenomas from complex fibroadenomas and phyllodes tumors.

Advantages and Superiority of the Impedimetric Tumor Detection System

ITDS has displayed encouraging results in a study involving 138 breast masses, achieving a sensitivity rate of 95%. This indicates that the device correctly identified the presence of tumors in 95 out of 100 cases. Additionally, the system has a specificity of 89% and an overall accuracy of 90%. These metrics indicate that ITDS has the potential to enhance the precision and efficacy of breast cancer screening, resulting in timelier detection and improved outcomes for patients.

Hospital Tech (ITDS)

Hospitech Cancer Care Innovations Company is at the forefront of revolutionizing cancer diagnosis with its state-of-the-art devices. These devices, including the Cancer Diagnostic Probe (CDP), (ITDS), Electrical Endoscopy Mass Detection (EMD), and ElectroChemoTherapy (ECT) & Gamma Probe , are designed to enhance the detection and treatment of cancer. Backed by research, publications, and patents, these instruments offer precise results for early diagnosis and improved patient outcomes. The company is dedicated to making a significant impact in the healthcare industry's battle against cancer, supported by a committed team and unwavering determination. Impedimetric Tumor Detection System is a revolutionary device that significantly enhances the accuracy of tumor detection. With a sensitivity of 95% and specificity of 89%, it ensures reliable identification of breast tumors, minimizing false negatives and positives. ITDS’s innovative technology has earned several US patents and is recognized in numerous scientific publications. By facilitating early detection, ITDS improves patient outcomes and supports healthcare providers in delivering superior care, making it a valuable investment for any medical facility.

Technology of (ITDS)

Using ITDS makes it possible to differentiate BI-RADS3 breast masses that require periodic follow-ups from BI-RADS4 and above, which require more examination through biopsy or excision, with higher accuracy than conventional imaging methods. This device’s findings reveal the dielectric properties of cells as a result of their pathophysiological changes during cancer, such as increased cell size, cell membrane permeability, alterations in water content within the cell, and so on. It is primarily employed in the diagnosis of Borderline Breast Diseases. While not all types of masses in this category are inherently malignant, they are more likely to become precancerous or high-risk masses over time compared to other normal breast masses. Therefore, based on breast surgery standards, it is preferable to remove them from the body.

The Impedimetric Tumor Detection System comes with advanced capabilities, including the detection of Borderline Breast Diseases (BBDs), aiding in the early diagnosis of breast cancers, and improving the precision of sampling in large masses by identifying the most pathological area within the mass. This device also incorporates the following features:

Features of (ITDS)

Assisting radiologists and surgeons identify BI-RADS3 masses requiring sampling or excision.
Detection of Borderline Breast Diseases (BBDs)
Helping to diagnose early-stage breast cancers
Especially beneficial for patients with a family history of breast cancer
Beneficial for patients having dense fibro glandular breasts (that are challenging cases in mammographically evaluations)
Beneficial for pregnant women
Increasing the accuracy of sampling in large masses by determining the most pathological part of the mass
93% accuracy in the clinical trial with 138 Breast masses